Target intelligence / Profile preview

Presenilin enhancer 2–ATP6AP1–vacuolar-type H+-ATPase complex (PEN2–ATP6AP1–v-ATPase)

Target
PEN2–ATP6AP1–v-ATPase
Molecular classification
Protein complex, Enzyme, Transporter, Metabolic sensor, Receptor
01

Overview

The Presenilin enhancer 2 (PEN-2)–ATP6AP1–vacuolar-type H+-ATPase (v-ATPase) complex is a multi-protein assembly on the lysosomal membrane that serves as a critical junction between cellular energy status and metabolic signaling (Lin et al., 2022, Nature). PEN-2, traditionally recognized as an essential subunit of the gamma-secretase complex involved in the proteolytic processing of the amyloid precursor protein (APP) (UniProt Q9NZ42), has been recently identified to function as a direct sensor for cytosolic glucose. When glucose levels are low, PEN-2 binds to the ATP6AP1 (Ac45) subunit of the v-ATPase, facilitating the recruitment of the AXIN-LKB1 complex to the lysosome to activate AMP-activated protein kinase (AMPK) (PubMed 35322231). This interaction effectively couples the cell's nutrient-sensing machinery with the v-ATPase proton pump, which is responsible for maintaining the acidic environment necessary for lysosomal degradation. Because of its dual role in both metabolic regulation and neurodegeneration-linked proteolysis, this complex is a high-interest therapeutic target for conditions such as type 2 diabetes, obesity, and Alzheimer's disease. However, pharmacological modulation of this complex poses significant challenges, as disrupting PEN-2's function could interfere with Notch signaling or lead to lysosomal dysfunction (Lin et al., 2022, Nature).

Other names
PEN2-ATP6AP1 complexPEN-2-v-ATPase complexPresenilin enhancer 2-ATP6AP1-v-ATPase lysosomal complexPSENEN-ATP6AP1-v-ATPase complex
02

Mechanism of action

Facilitates lysosomal AMPK activation in response to low glucose levels by bridging the v-ATPase complex and AMPK (Lin et al., 2022, Nature).

03

Biological functions

Glucose sensingLysosomal acidificationAMPK activationGamma-secretase-mediated proteolysisSignal transduction
04

Disease associations

Alzheimer's diseaseType 2 diabetesMetabolic syndromeCancerNeurodegenerative disease
05

Safety considerations

Inhibition of Notch signaling (due to PEN-2's role in gamma-secretase)Lysosomal acidification defectsSystemic metabolic disruptionPotential for Notch signaling toxicity
06

Interacting drugs

Glucose (endogenous ligand)

1 more in the full profile.

07

Biomarkers

Phosphorylated AMPK (p-AMPK Thr172)Lysosomal pHAmyloid-beta 42/40 ratioBlood glucose levels

Beyond the preview

Go deeper on Presenilin enhancer 2–ATP6AP1–vacuolar-type H+-ATPase complex (PEN2–ATP6AP1–v-ATPase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presenilin enhancer 2–ATP6AP1–vacuolar-type H+-ATPase complex (PEN2–ATP6AP1–v-ATPase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call